专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5670493A Aminophenylphosphonic acid compounds 失效
标题翻译：氨基苯膦酸化合物
公开(公告)号：US5670493A
公开(公告)日：1997-09-23
申请号：US684469
申请日：1996-07-19
申请人： Alex Cordi , Patrice Desos , Angela D. Morris , Ghanem Atassi
发明人： Alex Cordi , Patrice Desos , Angela D. Morris , Ghanem Atassi
IPC分类号： A61K31/66 , A61K31/665 , A61K31/67 , A61K31/675 , A61P27/02 , A61P35/00 , C07F9/38 , C07F9/40 , C07F9/572 , C07F9/655 , C07F9/6553
CPC分类号： C07F9/655345 , C07F9/3834 , C07F9/3882 , C07F9/4021 , C07F9/5728 , C07F9/65515
摘要： A compound of formula (I): ##STR1## in which: R.sub.1, R.sub.2, which may be identical or different, represent hydrogen or halogen, or alkyl, alkoxy, nitro or trihalomethyl, X represents CO, SO.sub.2 or CH.sub.2, A.sub.1 represents any one of the groups as defined in the description, A.sub.2 represents --(CH.sub.2).sub.n or --CH.dbd.CH--, R.sub.3, R.sub.4, which may be identical or different, represent hydrogen or alkyl, its isomers as well as its addition salts with a pharmaceutically acceptable base and medicinal product containing the same are useful as angiogenesis inhibitors.
摘要翻译：式（I）化合物：其中：R 1，R 2可以相同或不同，表示氢或卤素，或烷基，烷氧基，硝基或三卤甲基，X表示CO，SO 2或CH 2， A1表示说明书中定义的任何一个基团，A 2表示 - （CH 2）n或-CH = CH-，R 3，R 4可以相同或不同，表示氢或烷基，其异构体及其加成与药学上可接受的碱的盐和含有它们的药物可用作血管发生抑制剂。

2. 发明授权

US5424464A p-[Bis(2-chloroethyl)amino]phenylalanine compounds 失效
标题翻译：对 - [双（2-氯乙基）氨基]苯丙氨酸化合物
公开(公告)号：US5424464A
公开(公告)日：1995-06-13
申请号：US170055
申请日：1993-12-20
申请人： Alex Cordi , Angela D. Morris , Ghanem Atassi
发明人： Alex Cordi , Angela D. Morris , Ghanem Atassi
IPC分类号： A61K31/215 , A61P35/02 , C07C227/18 , C07C229/40 , C07C229/42 , C07C233/18 , C07C233/45 , C07C271/22 , C07C235/00
CPC分类号： C07C229/42 , C07C271/22
摘要： Antileukemic compounds of formula (I): ##STR1## in which: R.sup.1 represents hydrogen, linear or branched (C.sub.1 -C.sub.6)-alkoxycarbonyl or substituted or unsubstituted phenylalkoxycarbonyl,R.sup.2 represents any one of the following groups: ##STR2## in which: R.sub.3 or R.sub.4, which are identical or different, represent linear or branched (C.sub.6 -C.sub.19)-alkyl or linear or branched (C.sub.6 -C.sub.19)-alkenyl, and antileukemic products containing the same.
摘要翻译：式（I）的抗白血病化合物：其中：R1表示氢，直链或支链（C1-C6） - 烷氧基羰基或取代或未取代的苯基烷氧基羰基，R2表示以下基团中的任一个：（I）（C）其中：R3或R4相同或不同，表示直链或支链（C6-C19） - 烷基或直链或支链（C6-C19） - 烯基，和含有相同的抗白血病产品。

3. 发明授权

US06548515B1 Dihydrofuro[3,4-b]quinolin-1-one compounds 失效
标题翻译：二氢呋喃并[3,4-b]喹啉-1-酮化合物
公开(公告)号：US06548515B1
公开(公告)日：2003-04-15
申请号：US09718917
申请日：2000-11-22
申请人： Henri-Philippe Husson , Sylviane Giorgi-Renault , Christophe Tratrat , Ghanem Atassi , Alain Pierre , Pierre Renard , Bruno Pfeiffer
发明人： Henri-Philippe Husson , Sylviane Giorgi-Renault , Christophe Tratrat , Ghanem Atassi , Alain Pierre , Pierre Renard , Bruno Pfeiffer
IPC分类号： A61K314741
CPC分类号： C07D491/04 , C07D219/06 , C07D221/16 , C07D221/18 , C07D491/14 , C07D495/04
摘要： The invention relates to compound of formula (I): wherein: represents a single or double bond, R0 represents hydrogen or hydroxy or alkoxy, R1 and R2, which are identical or different, each represents hydrogen or halogen or alkyl, alkoxy, hydroxy, polyhaloalkyl, nitro or optionally substituted amino or wherein m represents an integer such that 1≦m≦4, or form together with the carbon atoms carrying them an aromatic or non-aromatic, mono- or bi-cyclic group having from 5 to 12 ring members and optionally containing 1 or 2 hetero atoms selected from O, S and N, R3 represents hydrogen or aryl, heteroaryl, cycloalkyl, optionally substituted alkyl or a group of formula COR7 wherein R7 represents aryl, optionally substituted alkyl, optionally substituted amino or OR10 wherein R10 represents aryl or optionally substituted alkyl, X represents oxygen or sulphur or —CH2— or —CH2—CH2—, Ar represents aryl, heteroaryl or arylalkyl, its optical isomers, its hydrates, solvates, and also its addition salts with a pharmaceutically acceptable acid. Medicinal products containing the same are useful in the treatment of cancer.
摘要翻译：本发明涉及式（I）的化合物：其中：表示单键或双键，R 0表示氢或羟基或烷氧基，R 1和R 2相同或不同，各自表示氢或卤素或烷基，烷氧基，羟基，多卤代烷基，硝基或任选取代的氨基或其中m表示1≤= m = 4的整数，或与带有带有5至12个环成员的芳族或非芳族单环或双环基团的碳原子一起形成，并且任选地含有1或 2个选自O，S和N的杂原子，R 3表示氢或芳基，杂芳基，环烷基，任选取代的烷基或式COR7基团，其中R7表示芳基，任选取代的烷基，任选取代的氨基或OR 10，其中R 10表示芳基或任选地取代的烷基，X表示氧或硫或-CH 2 - 或-CH 2-CH 2 - ，Ar表示芳基，杂芳基或芳基烷基，其光学异构体，其水合物，溶剂合物，以及其与药学上可接受的酸的加成盐。含有它们的医药产品可用于治疗癌症。

4. 发明授权

US6071945A 8H-thieno-[2,3-b]pyrrolizin-8-one compounds 失效
标题翻译： 8H-噻吩并[2,3-b]吡咯啉-8-酮化合物
公开(公告)号：US6071945A
公开(公告)日：2000-06-06
申请号：US361064
申请日：1999-07-26
申请人： Sylvain Rault , Cecile Enguehard , Jean-Charles Lancelot , Max Robba , Ghanem Atassi , Alain Pierre , Daniel-Henri Caignard , Pierre Renard
发明人： Sylvain Rault , Cecile Enguehard , Jean-Charles Lancelot , Max Robba , Ghanem Atassi , Alain Pierre , Daniel-Henri Caignard , Pierre Renard
IPC分类号： A61K31/00 , A61K31/40 , A61K31/407 , A61P35/00 , C07D495/14
CPC分类号： C07D495/14 , Y02P20/55
摘要： A compound selected from those of formula (I): ##STR1## wherein: R.sub.1 represents hydrogen, halogen, alkyl, nitro, hydroxy, alkoxy, trihaloalkyl, trihaloalkoxy or optionally substituted amino,R.sub.2 represents optionally substituted aryl or heteroaryl,R.sub.3 represents hydrogen, halogen, alkyl, nitro, hydroxy, alkoxy, trihaloalkyl, trihaloalkoxy or optionally substituted amino,their isomers and addition pharmaceutically-acceptable acid or base salts thereof and medicinal products containing the same are useful in the treatment of cancer.
摘要翻译：选自式（I）的化合物：其中：R 1表示氢，卤素，烷基，硝基，羟基，烷氧基，三卤代烷基，三卤代烷氧基或任选取代的氨基，R 2表示任选取代的芳基或杂芳基，R 3表示氢，硝基，羟基，烷氧基，三卤代烷基，三卤代烷氧基或任选取代的氨基，它们的异构体及其加成药学上可接受的酸或碱盐和含有它们的药物可用于治疗癌症。

5. 发明授权

US5595976A Tetrahydropyran compounds 失效
标题翻译：四氢吡喃化合物
公开(公告)号：US5595976A
公开(公告)日：1997-01-21
申请号：US521189
申请日：1995-08-30
申请人： David Billington , Gilbert Dorey , Pascale Leon , Ghanem Atassi , Alain Pierre , Michael Burbridge , Nicolas Guilbaud
发明人： David Billington , Gilbert Dorey , Pascale Leon , Ghanem Atassi , Alain Pierre , Michael Burbridge , Nicolas Guilbaud
IPC分类号： C07H9/02 , A61K31/70 , A61K31/7028 , A61P9/00 , A61P29/00 , A61P35/00 , C07H9/04 , C07H15/04 , C07H15/10 , C07H15/18 , C07H15/26 , A61K37/00 , C07H3/00
CPC分类号： C07H9/04 , C07H15/04 , C07H15/10 , C07H15/26
摘要： A compound selected from those of formula (I): ##STR1## in which: A either represents --OR.sub.6, and B represents --CH.sub.2 --X,or, together with B and the carbon atom carrying them, forms an oxygen-containing heterocycle selected from oxirane, 2,2-dimethyl[1,3]dioxolane and [1,3]dioxolan-2-one,and R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6 and X are as defined in the description.
摘要翻译：选自式（I）的化合物：其中：A表示-OR6，B表示-CH2-X，或者与B和携带它们的碳原子一起形成氧 - 含有杂环的环氧乙烷，2,2-二甲基[1,3]二氧戊环和[1,3]二氧戊环-2-酮，R1，R2，R3，R4，R5，R6和X如说明书中所定义。

6. 发明授权

US5266576A N-myristoyl transferase inhibitors 失效
标题翻译： N-肉豆蔻酰转移酶抑制剂
公开(公告)号：US5266576A
公开(公告)日：1993-11-30
申请号：US833301
申请日：1992-02-10
申请人： Michel Vincent , Georges Remond , Bernard Portevin , Jean-Albert Boutin , Ghanem Atassi
发明人： Michel Vincent , Georges Remond , Bernard Portevin , Jean-Albert Boutin , Ghanem Atassi
IPC分类号： A61K31/195 , A61K31/198 , A61K31/397 , A61K31/40 , A61K31/415 , A61K31/435 , A61K31/675 , A61P31/12 , A61P31/16 , A61P31/18 , A61P31/22 , A61P35/00 , A61P35/02 , A61P37/04 , C07C233/48 , C07C233/51 , C07C233/87 , C07C235/06 , C07C235/12 , C07C323/60 , C07D207/16 , C07D207/26 , C07D207/277 , C07D209/26 , C07D209/44 , C07D211/60 , C07D211/78 , C07D217/22 , C07D217/26 , C07D233/54 , C07D233/64 , C07D317/24 , C07D453/06 , C07D471/04 , C07D487/04 , C07D487/08 , C07D487/14 , C07F9/38 , C07F9/40 , C07F9/44 , C07F9/48 , A61K31/44
CPC分类号： C07D207/277 , C07C233/48 , C07C233/51 , C07C233/87 , C07C235/12 , C07C323/60 , C07D209/26 , C07D209/44 , C07D211/60 , C07D217/26 , C07D233/64 , C07D317/24 , C07D453/06 , C07D471/04 , C07F9/3808 , C07F9/3882 , C07F9/4006 , C07F9/4021 , C07F9/4056 , C07F9/4465 , C07F9/4816 , C07C2101/14
摘要： The invention relates to a compound of formula (I): ##STR1## which can be used as N-myristoyltransferase inhibitors, in which R.sub.1 represents hydrogen, substituted or unsubstituted (C.sub.1 -C.sub.6) alkyl, substituted or unsubstituted phenyl, (C.sub.3 -C.sub.7) cycloalkyl methyl, substituted or unsubstituted (imidazolyl-2-yl)methyl, substituted or unsubstituted (indol-3-yl)methyl or (1-azaindolizin-2-yl)methyl,R.sub.2, R.sub.3, which are identical or different, represent hydrogen or (Cl-C6) alkyl,or when R.sub.1 represents hydrogen, R.sub.2 and R.sub.3 form with the carbon and nitrogen atoms to which they are attached, a mono-, bi- or tricyclic heterocycle,X represents --CO--, --SO.sub.2 --, --PO(OH)--,Y represents --COR.sub.5 or --POR.sub.6 R.sub.6 ',R.sub.4 represents substituted or unsubstituted, linear or branched (C.sub.6 -C.sub.21) alkyl in which, depending on the individual case, one or more methylene may be replaced by oxygen or sulfur or by a p-phenylene ring,their isomers, diastereoisomers and epimers as well as their addition salts with a pharmaceutically acceptable acid or base.
摘要翻译：本发明涉及可用作N-肉豆蔻酰转移酶抑制剂的式（I）化合物：其中R1表示氢，取代或未取代的（C1-C6）烷基，取代或未取代的苯基，（ C 3 -C 7）环烷基甲基，取代或未取代的（咪唑基-2-基）甲基，取代或未取代的（吲哚-3-基）甲基或（1-氮杂吲哚哩啶-2-基）甲基，R 2，R 3，其相同或不同的，代表氢或（C 1 -C 6）烷基，或当R 1表示氢时，R 2和R 3与它们所连接的碳原子和氮原子一起形成单，双或三环杂环，X表示-CO-， -SO 2 - ， - PO（OH） - ，Y表示-COR 5或-POR 6 R 6'，R 4表示取代或未取代的直链或支链（C6-C21）烷基，其中根据个别情况，一个或多个亚甲基可以由氧或硫或对亚苯基环，其异构体，非对映异构体和差向异构体代替，以及它们与药学上的加成盐可溶性酸或碱。

7. 发明授权

US5225405A Use of triazine and pyrimidine compounds for obtaining medicaments that reverse resistance to anti-cancer and anti-malarial agents 失效
标题翻译：使用三嗪类和吡嗪类化合物来获得反抗抗癌药和抗疟剂的药物
公开(公告)号：US5225405A
公开(公告)日：1993-07-06
申请号：US765679
申请日：1991-09-26
申请人： Bernard Paramelle , Xavier Leverve , Gilbert Regnier , Alain Dhainaut , Ghanem Atassi
发明人： Bernard Paramelle , Xavier Leverve , Gilbert Regnier , Alain Dhainaut , Ghanem Atassi
IPC分类号： A61K31/505 , A61K31/53 , A61P33/02 , A61P35/00 , C07D239/50 , C07D251/44 , C07D401/04 , C07D405/06 , C07D409/06
CPC分类号： A61K31/505 , A61K31/53
摘要： The invention relates to the use, for obtaining medicaments that reverse resistance to anti-cancer and anti-malarial agents, of compounds of formula I: ##STR1## in which A is --CH-- or nitrogen,and B, R.sub.1, R.sub.2 and R.sub.3 are as defined in the description,and their physiologically tolerable acid addition salts.
摘要翻译：本发明涉及用于获得式I化合物：其中A为-CH-或氮的式（I）化合物，B，R 1，R 2， R2和R3如说明书中所定义，及其生理上可耐受的酸加成盐。

8. 发明授权

US06878746B2 Carbamate and thiocarbamate podophyllotoxin derivatives, preparation method and pharmaceutical compositions containing them 失效
标题翻译：氨基甲酸酯和硫代氨基甲酸酯鬼臼毒素衍生物，制备方法和含有它们的药物组合物
公开(公告)号：US06878746B2
公开(公告)日：2005-04-12
申请号：US10312175
申请日：2001-06-19
申请人： Claude Monneret , Emmanuel Bertounesque , Philippe Meresse , Ghanem Atassi , Alain Pierre , John Hickman , Bruno Pfeiffer , Pierre Renard
发明人： Claude Monneret , Emmanuel Bertounesque , Philippe Meresse , Ghanem Atassi , Alain Pierre , John Hickman , Bruno Pfeiffer , Pierre Renard
IPC分类号： A61K31/36 , A61P35/00 , C07D493/04 , A61K31/365
CPC分类号： C07D493/04 , Y02P20/55
摘要： A compound selected from these of formula (I): wherein: R1 represents hydrogen, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxycarbonyl, aryloxycarbonyl, arylalkoxycarbonyl, heterocycloalkoxycarbonyl, alkylsulfonyl, arylsulfonyl, arylalkylsulfonyl or phosphono, R2 represents oxygen or sulphur, R3 represents hydrogen or alkyl, cycloalkyl or arylalkyl, X represents linear or branched (C1-C6)alkylene, R4 represents a group selected from amino optionally substituted by one or two groups, —N(R3)—X1—OR5 wherein R3, X1 and R5 are as defined in the description, —N(R3)—X1—NR6R7 wherein R3, X1, R6 and R7 are as defined in the description, hydroxy, alkoxy, aryloxy, —O—X1—OR5 wherein R5 and X1 are as defined in the description, and —O—X1—NR6R7 wherein R6, R7 and X1 are as defined in the description, its isomers, and also addition salts thereof with a pharmaceutically acceptable acid or base, and medical products containing the same which are useful in the treatment of cancer.
摘要翻译：选自这些式（I）的化合物：其中：R1表示氢，烷基，芳基，芳基烷基，杂芳基，杂芳基烷基，烷氧基羰基，芳氧基羰基，芳基烷氧基羰基，杂环烷氧基羰基，烷基磺酰基，芳基磺酰基，芳基烷基磺酰基或膦酰基，R2表示氧或硫，R3 表示氢或烷基，环烷基或芳基烷基，X表示直链或支链（C1-C6）亚烷基，R4表示选自任选被一个或两个基团取代的氨基的基团-N（R3）-X1-OR5，其中R3，X1和 R 5如说明书中所定义，-N（R3）-X1-NR6R7，其中R3，X1，R6和R7如说明书中所定义，羟基，烷氧基，芳氧基，-O-X1-OR5，其中R5和X1为和-O-X 1 -NR 6 R 7，其中R 6，R 7和X 1如说明书中所定义，其异构体及其与药学上可接受的酸或碱的加成盐，以及含有它们的医药产品可用在治疗癌症。

9. 发明授权

US06281198B1 9-(3,5-dimethoxyphenyl)-5,8,8a,9-tetrahydrofuro-[3′,4′:6,7]naphtho[2,3-d][1,3]dioxol-6(5aH)-one compounds 失效
标题翻译： 9-（3,5-二甲氧基苯基）-5,8,8a，9-四氢呋喃（3'，4'：6,7）萘并（2,3-d）（1,3）二氧杂环戊烯-6（5aH）一种化合物
公开(公告)号：US06281198B1
公开(公告)日：2001-08-28
申请号：US09697248
申请日：2000-10-26
申请人： Claude Monneret , Emmanuel Bertounesque , Philippe Meresse , Ghanem Atassi , Alain Pierre , Bruno Pfeiffer , Pierre Renard
发明人： Claude Monneret , Emmanuel Bertounesque , Philippe Meresse , Ghanem Atassi , Alain Pierre , Bruno Pfeiffer , Pierre Renard
IPC分类号： A61K31365
CPC分类号： C07D493/04 , Y02P20/55
摘要： Compound of formula (I): wherein: R represents: a group of formula (i): wherein X, Y and W are as defined in the description, or a group of formula (ii): —A—G (ii) wherein: A represents a single bond or an optionally substituted alkylene chain, G represents a group selected from hydrogen, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —OR2, —O—T1—NR3R4, —O—T1—NR2—T′1—NR3R4, —NR3R4, —NR2—T1—NR3R4, —NR2—T1—OR5, —NR2—T1—CO2R6, —NR2—T1—C(O)R6, —C(O)—NR3R4, —C(O)—NR2—T2, —O—C(O)T2, —O—C(S)—T2, —NR2—C(O)—T2, —NR2—C(S)—T2, —O—C(O)—O—T2, —O—C(O)—NR2—T2, —O—C(S)—O—T2, —O—C(S)—NR2—T2, —NR2—C(O)—O—T2, —NR2—C(O)—NR—T2, —NR2—C(S)—O—T2, —NR2—C(S)—NR6—T2 and —NR2—SO2—T3, wherein R2, R3, R4, R5, R6, T1, T′1, T2 and T3 are as defined in the description, R1 represents a group selected from hydrogen, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, heterocycloalkylcarbonyl, alkylsulphonyl, arylsulphonyl, arylalkylsulphonyl, phosphono, aryloxycarbonyl, alkoxycarbonyl and arylalkoxycarbonyl, its isomers, and also addition salts thereof with a pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful in the treatment of cancer.
摘要翻译：式（I）的化合物：其中：R表示：式（ⅰ）的基团：其中X，Y和W如说明书中所定义，或式（ⅱ）的基团：其中：A表示单键或任选取代的亚烷基链，G表示选自氢，环烷基，杂环烷基，芳基，杂芳基，-OR2，-O-T1-NR3R4，-O-T1-NR2-T'1-NR3R4，-NR3R4，-NR2 -T 1 -NR 3 R 4，-NR 2 -T 1 -OR 5，-NR 2 -T 1 -CO 2 R 6，-NR 2 -T 1 -C（O）R 6，-C（O）-NR 3 R 4，-C（O）-NR 2 -T 2，-OC （O）T 2，-OC（S）-T 2，-NR 2 -C（O）-T 2，-NR 2 -C（S）-T 2，-OC（O）-O-T 2，-OC（O） -T 2，-OC（S）-O-T2，-OC（S）-NR2-T2，-NR2-C（O）-O-T2，-NR2-C（O）-NR-T2， C（S）-O-T2，-NR2-C（S）-NR6-T2和-NR2-SO2-T3，其中R2，R3，R4，R5，R6，T1，T'1，T2和T3为 R 1表示选自氢，烷基，芳基，芳基烷基，杂芳基，杂芳基烷基，烷基羰基，芳基羰基，芳基烷基羰基，杂环烷基羰基，烷基磺酰基，芳基磺酰基，芳基烷基磺酰基，膦酰基，芳氧基羰基，烷氧基羰基和芳基烷氧基羰基，其异构体，以及其与药学上可接受的酸或碱的加成盐。含有该化合物的药物可用于治疗癌症。

10. 发明授权

US6162822A Bisimide compounds 失效
标题翻译：双酰亚胺化合物
公开(公告)号：US6162822A
公开(公告)日：2000-12-19
申请号：US221904
申请日：1998-12-28
申请人： Gilbert Lavielle , Patrick Hautefaye , Ghanem Atassi , Alain Pierre , Laurence Kraus-Berthier , Stephane Leonce
发明人： Gilbert Lavielle , Patrick Hautefaye , Ghanem Atassi , Alain Pierre , Laurence Kraus-Berthier , Stephane Leonce
IPC分类号： C07D221/10 , A61K31/435 , A61K31/47 , A61K31/473 , A61K31/55 , A61P35/00 , C07D209/80 , C07D401/12 , C07D403/12 , C07D519/00 , A01N43/38 , C07D487/00 , C07D487/02 , C07D491/00 , A61R31/40
CPC分类号： C07D209/80 , C09B57/08
摘要： A compound of formula (I) ##STR1## in which: m, and n, which may be identical or different, represent 0 or 1,X and Y, which may be identical or different, represent hydrogen or halogen or alky, trihaloalkyl, alkoxy, hydroxyl, cyano, nitro, amino, alkylamino or dialkylamino,Z represent a linear or branched C.sub.4 to C.sub.12 alkylene chain in which one or more --CH.sub.2 -- are optionally replaced by any one of the following atoms or groups: --NR--, --O--, --S--, --SO--, --SO.sub.2 --, or --CONH--, or by a substituted or unsubstituted heterocylcic,A forms, with two adjacent carbon atoms of the phenyl ring, a phenyl, naphthyl or tetrahydronaphthyl ring or a heterocycle, ##STR2## and medicinal products containing the same are useful as anticancer agent.
摘要翻译：式（I）化合物，其中m和n可以相同或不同，表示0或1，X和Y可以相同或不同，表示氢或卤素或烷基，三卤代烷基，烷氧基，羟基，氰基，硝基，氨基，烷基氨基或二烷基氨基，Z表示直链或支链的C 4至C 12亚烷基链，其中一个或多个-CH 2 - 任选被以下任何一个原子或基团取代：-NR-，-O- ，-S-，-SO-，-SO 2 - 或-CONH-，或通过取代或未取代的杂环A形式与苯环的两个相邻碳原子，苯基，萘基或四氢萘基环或杂环，含有该药物的药物可用作抗癌剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式